Tanaka Hidekazu, Yamauchi Yuki, Imanishi Junichi, Hatani Yutaka, Odajima Susumu, Okamoto Hiroshi, Hayashi Takatoshi, Hirata Ken-Ichi
Division of Cardiovascular Medicine, Department of Internal Medicine, Kobe University Graduate School of Medicine Kobe Japan.
Department of Cardiology, Hyogo Prefectural Awaji Medical Center Sumoto Japan.
Circ Rep. 2022 Sep 22;4(10):499-504. doi: 10.1253/circrep.CR-22-0067. eCollection 2022 Oct 7.
The association between heart rate (HR) reductions caused by ivabradine and left ventricular (LV) diastolic function in heart failure with preserved ejection fraction (HFpEF) remains uncertain because of off-label use. Thus, the present study investigated the effect of HR reductions by ivabradine on LV diastolic function in HFpEF patients. This study enrolled 16 HFpEF patients with HR ≥75 beats/min. After 3 months administration of ivabradine, no significant changes were observed in mitral inflow E and mitral e' annular velocities, B-type natriuretic peptide, or left atrial volume index, but there were significant improvements in global longitudinal strain. Ivabradine did not improve LV diastolic function for HFpEF patients with HR ≥75 beats/min. Because this may be due to some study limitations, further studies should be conducted.
由于伊伐布雷定属于超适应症用药，其降低心率（HR）与射血分数保留的心力衰竭（HFpEF）患者左心室（LV）舒张功能之间的关联仍不确定。因此，本研究探讨了伊伐布雷定降低心率对HFpEF患者LV舒张功能的影响。本研究纳入了16例HR≥75次/分钟的HFpEF患者。在给予伊伐布雷定3个月后，二尖瓣流入E峰和二尖瓣环e'速度、B型利钠肽或左心房容积指数均未观察到显著变化，但整体纵向应变有显著改善。伊伐布雷定对HR≥75次/分钟的HFpEF患者的LV舒张功能没有改善作用。由于这可能是由于一些研究局限性导致的，因此应进行进一步的研究。
